A phase 2 trial (NCT00854308) compared onartuzumab plus erlotininb versus placebo plus erlotinib (EGFR TKI) in intent-to-treat (ITT) and MET-positive populations for recurrent NSCLC [50]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.